Learning Objectives:
1. Categorize FDA approved ADCs in terms of their molecular characteristics
2. List and understand the landmark clinical trials leading to FDA approval of ADCs in breast cancer
3. Understand the drawbacks of IHC in determining ADC eligibility
Session date:
05/09/2024 - 8:00am to 9:00am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Dan Peiffer MD, PhD